Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Comparative Study of 5-Aminolevulinic Acid (5-ALA) and Intraoperative MRI (iMRI) to Enhance Completeness of Resection of Glioblastoma

NCT01575275 is registered in ClinicalTrials.gov with Michael Vogelbaum, MD, PhD as lead sponsor.

NCT NCT01575275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01575275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Comparative Study of 5-Aminolevulinic Acid (5-ALA) and Intraoperative MRI (iMRI) to Enhance Completeness of Resection of Glioblastoma
Lead sponsor
Michael Vogelbaum, MD, PhD
Phase
Phase 2
Overall status
Terminated
Start date
May 31, 2012
Completion date
August 31, 2014
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

adult giant cell glioblastoma, adult glioblastoma, adult gliosarcoma, recurrent adult brain tumor